Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor
cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop
tumor cells from dividing so they stop growing or die. Combining erlotinib with cisplatin may
kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib and cisplatin in
treating patients who have recurrent or metastatic head and neck cancer.